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Abstract
Aggressive epithelial ovarian cancer (EOC) is genetically and epigenetically distinct from normal
ovarian surface epithelial cells (OSE) and early neoplasia. Co-expression of epithelial and
mesenchymal markers in EOC suggests an involvement of epithelial-mesenchymal transition (EMT)
in cancer initiation and progression. This phenomenon is often associated with acquisition of a stem
cell-like phenotype and chemoresistance that correlate with the specific gene expression patterns
accompanying transformation, revealing a plasticity of the ovarian cancer cell genome during
disease progression.
Differential gene expressions between normal and transformed cells reflect the varying
mechanisms of regulation including genetic changes like rearrangements within the genome, as well
as epigenetic changes such as global genomic hypomethylation with localized promoter CpG island
hypermethylation. The similarity of gene expression between ovarian cancer cells and the stem-like
ovarian cancer initiating cells (OCIC) are surprisingly also correlated with epigenetic mechanisms
of gene regulation in normal stem cells. Both normal and cancer stem cells maintain genetic
flexibility by co-placement of activating and/or repressive epigenetic modifications on histone H3.
The co-occupancy of such opposing histone marks is believed to maintain gene flexibility and such
bivalent histones have been described as being poised for transcriptional activation or epigenetic
silencing. The involvement of both-microRNA (miRNA) mediated epigenetic regulation, as well as
epigenetic-induced changes in miRNA expression further highlight an additional complexity in
cancer stem cell epigenomics.
Recent advances in array-based whole-genome/epigenome analyses will continue to further unravel
the genomes and epigenomes of cancer and cancer stem cells. In order to illuminate phenotypic
signatures that delineate ovarian cancer from their associated cancer stem cells, a priority must lie
in the expansion of current technologies and further implementation of bioinformatics to handle
the complexity of the cancer epigenome and the various networks that coordinate disease initiation
and progression. Great potential lies in the translation of these findings into epigenetic-based
therapies. Additionally, targeting chemo-resistant cancer stem cells may provide a much needed
breakthrough in treatment of advanced ovarian cancer and chemoresistant disease.
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Epithelial ovarian cancer (EOC) is the eighth most com-
mon cancer among women and causes more deaths than
any other female reproductive tract cancer [1]. The Amer-
ican Cancer Society estimates that about 21,650 new cases
of ovarian cancer will be diagnosed in the United States
during 2008. A woman's risk of getting invasive ovarian
cancer during her lifetime is about 1 in 71, and her life-
time chance of dying from invasive ovarian cancer is
about 1 in 95 [2]. Ovarian cancer strikes silently, usually
revealing no obvious symptoms until disease advances to
a metastatic stage. The standard treatment is cytoreductive
surgery followed by platinum/taxane regimens, which
results in clinically complete remissions in > 70% of
patients. However, relapse occurs in > 90% of those
responders, at which point the disease is essentially incur-
able. Drug resistance remains the major therapeutic bar-
rier in ovarian cancer, and current second-line therapies
have not proven to be effective [3].
Early detection is needed, so it is essential to understand
ovarian cancer initiation as well as what drives its progres-
sion. Although some EOC have been suggested to origi-
nate from the fallopian tube [4], a majority of reports
continue to support the earlier concept that ovarian can-
cer arises from the ovarian surface epithelium (OSE) [5].
Co-expression of epithelial and mesenchymal markers
found in EOC highlights the plasticity of the OSE during
epithelial-mesenchymal transition (EMT), and may con-
tribute to neoplastic transformation and acquisition of
stemness [6]. Indeed, the identification of ovarian cancer
stem and progenitor-like cells (CSCs) [7], ovarian cancer
initiating cells (OCIC) [8] and ovarian side-population
(SP) cells [9] strongly suggests the involvement of a mech-
anism like the inherent EMT of OSE cells to confer a phe-
notypic and genetic plasticity that predisposes them to
neoplastic transformation and acquisition of stem cell
characteristics.
Cancer initiation from the ovarian surface 
epithelium (OSE)
Normal OSE, epithelial-mesenchymal transition and 
inclusion cysts
The OSE is a single layer of cuboidal epithelial cells cover-
ing the entire surface of the ovary and is responsible for
material transport to and from the peritoneal cavity as
well as repair of ovulatory rupture [5]. In the 1980s, the
first tissue culture systems for OSE from different species
[10-14], including human [15,16], were developed. Sub-
sequently, information about the normal functions of
OSE expanded rapidly, and established the relationship of
OSE with ovarian adenocarcinomas [16,17]; approxi-
mately 90% of human ovarian cancers arise from the OSE
[13,18-20].
The OSE is considered a primitive type of epithelium and
unlike most normal epithelia, expresses both epithelial
and mesenchymal markers. Epithelial markers typically
expressed include keratins, while vimentin, N-cadherin
and MUC1 are the mesenchymal markers that are
expressed in the OSE [5]. During the postovulatory repair
process and in culture, OSE cells undergo EMT as a part of
the wound healing process following ovarian rupture or
in response to cell culture conditions [21-24]. Wound
healing following ovarian rupture is occasionally accom-
panied by cell migration across the ruptured surface. The
entrapment of OSE in ovarian stroma leads to the forma-
tion of inclusion cysts [25] that are thought to represent
the site of origin of EOC [5]. In support of this hypothesis,
early malignant changes are induced in OSE-lined inclu-
sion cysts, including expression of the EOC marker CA125
in OSE of inclusion cysts but not in normal OSE cells [26-
28].
While the normal OSE is protected from the underlying
stromal signaling due to separation by a thick cellular
layer of the tunica albuginea, inclusion cysts directly
expose otherwise naïve OSE to stromal signaling and alter
normal gene expression patterns [5]. Such stromal-
derived growth factors have been suggested to continue
promoting EMT, resulting in neoplastic transformation of
OSE within the inclusion cysts [5]. Further, cyst-entrapped
OSE may also promote their own transformation through
cytokines, growth factors, and other bioactive molecules
that accumulate within the confines of inclusion cysts
[29,30]. Frequent ovulation contributes to increased EOC
risk due to repeated rupture and repair of the OSE. There
is convincing evidence that prevention of ovarian rupture,
through multiparity or oral contraceptives, is protective
against EOC (reviewed in [20]).
Genetics and epigenetics of cancer initiation and 
progression
Normal OSE expresses N-cadherin, and little to no E-cad-
herin. EOCs however, express E-cadherin, especially at the
initial phases of transformation; E-cadherin has been
shown to induce EMT in OSE cells and is considered an
initial step in transformation [16]. E-cadherin expression
is reduced in metastasizing cells when cell-cell junctions
are abrogated to facilitate cell migration – an adaptation
of normal EMT [31]. The phenotypic plasticity of the OSE
during disease initiation and progression reflects a flexi-
bility of inherent gene expression that is a pre-requisite for
EMT. This feature could be an underlying step facilitating
neoplastic transformation, besides accounting for the het-
erogeneity for expression of epithelial, mesenchymal and
'stemness' genes and exhibit complex patterns of histolog-
ical differentiation [6,32].Page 2 of 11
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Comparative genomic hybridization (CGH) of early and
late-stage ovarian cancers indicated that chromosome
losses are more common than gains in the early-stage
tumors, while chromosomal gain and amplifications were
mainly confined to the late-stage ovarian tumors [33].
Early EOC may therefore already possess genetic abnor-
malities that are further propagated in advanced disease
states.
Normal OSE, early EOC, and advanced disease are easily
classified based on differential gene expression [33-40].
Such array-based findings have been instrumental in
understanding the progression of ovarian cancer. Expres-
sion profiling of epithelial ovarian cancer of varying his-
tologies has identified genetic signatures that distinguish
the major histological types of ovarian carcinoma [41-46].
BRAF and KRAS mutations are common in serous border-
line tumors and low-grade serous carcinomas, but very
rare in most serous carcinomas of high-grade. Loss of het-
erozygosity (LOH), microsatellite instability and muta-
tions in PTEN and/or β-catenin genes define
endometrioid carcinomas. Clear cell carcinomas are more
frequently associated with microsatellite instability [47].
Phosphatidyl inositol 3 kinase (PI3K) and its downstream
effector AKT2 have also shown to be amplified in associa-
tion with a significant proportion of ovarian carcinomas
especially the aggressive sub-types [48,49], while the PI3K
inhibitor PTEN is mutated in a significant proportion of
endometrioid ovarian carcinomas [50]. These findings
provide insights into the molecular mechanisms for each
clinical phenotype.
EOC expresses a number of genes not found in OSE,
including CA125 [5], now an established EOC biomarker
[51], folate receptor [52-54] and HE4 [40] that are also
overexpressed during disease progression. Upregulation
of growth signaling pathways, including Bcr-Abl, Erb-B,
Her2/neu, VEGF, and COX-2 are also found in EOC, and
contribute to the understanding of EOC progression [55].
microRNA (miRNA) microarrays have also identified a
number of over-and-under-expressed miRNA in ovarian
cancer; such findings may also become future biomarkers
or drug targets [56].
Cancer epigenetics
A long-standing issue in the field is the sequence of molec-
ular events that lead to epigenetic gene silencing. Clear
evidence shows CpG island hypermethylation plays a
major role in mediating silencing in cancer and is an early
event in cancer development. In some cases, it may even
precede the neoplastic process. Because of their heritable
nature, hypermethylated CpG islands leave 'molecular
footprints' in evolving cancer cells that can be used as
molecular markers to reconstruct epigenetic progression
during tumorigenesis [57].
As EOC is recognized to be a "methylating" type of cancer;
disease progression is strongly linked with silencing of
tumor suppressor genes (TSGs) [57,58]. Aberrant epige-
netic alterations, represented by loss of DNA methylation
leading to global genome hypomethylation as well as gain
of promoter-associated CpG methylation, are strongly
associated with all stages of tumor formation and progres-
sion [57]. Epigenetic remodeling is most obvious at pro-
moter regions of genes that regulate important cell
functions [59]. Epigenetic alterations also extend to devi-
ant patterns of histone modifications [60,61] and deregu-
lation of microRNA expression in human epithelial
ovarian cancer [62,63]; however, the underlying mecha-
nism and consequences to genome-wide transcriptional
changes in cancer are as yet, largely unknown.
Several techniques including methylation-specific PCR
(MSP) and bisulfite sequencing are often used to identify
temporal acquisition of methylation at individual CpGs
within a gene promoter. Chromatin immunoprecipita-
tion (ChIP), using antibodies against epigenetically
marked cytosine residues or histones, captures DNA and
permits visualization of gene promoters associated with
these marks. A temporal theory of epigenetic gene repres-
sion has been proposed from data generated from com-
bining MSP and ChIP-chip technologies. This suggests the
primary event in transcriptional repression to be chroma-
tin remodeling that in turn, is achieved through histone
deacetylation and methylation. Such temporal under-
standing of CpG island hypermethylation has proved use-
ful for molecular classification of different ovarian cancer
types [57], while establishment of a "histone code" of epi-
genetic marks has provided chromatin signatures that
may also be predictive of EOC progression [64-66].
ChIP'ped DNA applied to DNA microarrays (ChIP-chip)
is now used to achieve larger-scale epigenetic maps. The
intense focus on whole genome-scale epigenetics has
spurned the combination of ChIP technology with high-
throughput DNA sequencing, yielding ChIP-sequencing
(ChIP-seq) technology [67]. Further extension of current
bioinformatics analysis software platforms is proving
essential for mining and interpreting these massive data-
sets.
Cancer stem cells
The recently described cancer stem cell (CSC) hypothesis
[68] postulates that tumorigenic potential is limited to a
very small subpopulation of cells within the tumor that
possess stem-cell properties [69]. The observation that
epidermal cancers may arise long after the initial exposure
to carcinogen implies that the original carcinogenic event
must have occurred in a long-lived stem cell populationPage 3 of 11
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ther generations of cells and a resulting tumor mass. CSCs
have been identified in several cancers including leukemia
[71], brain [72], colon [73], breast [74], and the list is
increasing with a fair regularity. The first report of the
involvement of stem cells in ovarian cancer came from
our lab and described the establishment of an extensive in
vitro system from the ascites fluid of an epithelial ovarian
cancer patient. This comprised of nineteen spontaneously
immortalized stem cell clones, each of which is derived
from a single cell [6]. Of these, two had tumorigenic and
stem cell potential, and could sequentially propagate
tumors sequentially in mice over several generations,
revealing their identity as ovarian cancer stem cells [7].
Soon after, CSCs were also isolated from ovarian tumors
and cell lines by fluorescence-assisted cell sorting (FACS)
based on their ability to differentially efflux the DNA-
binding dye Hoechst 33342 and expression of the vera-
pamil-sensitive, multi-drug resistance gene BCRP1. This
property defines a minute fraction of stem cells termed as
the side-population (SP) stem cells [9]. The SP population
was further found to be tumorigenic and withstood their
identity as CSCs in all the classical stem cell and tumori-
genecity assays. More recently, a population of normal
murine OSE have been shown to exhibit stem/progenitor
cell characteristics, including dye-retention providing evi-
dence for a putative somatic stem/progenitor cells [75].
Another recently described report in ovarian cancer
describes the application of expression of stem-cell surface
markers CD44 and CD117 (c-kit) to sort out ovarian can-
cer initiating cells viz. OCICs in tumors [8]. The primary
ovarian tumor-derived OCIC were capable of serial prop-
agation of the original tumor further establishing them to
be essential contributors to tumor growth.
Similarity to stem cells
Normal stem cells are generally quiescent and possess
long-term survival characteristics including self-renewal,
DNA repair, and expression of membrane-bound drug-
efflux transporter molecules in the cell membrane
towards providing resistance to environmental insults.
Most, if not all these traits have now been demonstrated
in their malignant counterparts [76]. CSCs express a com-
plement of such stem cell markers including Octamer 4
(Oct4), Nanog, nestin, B-lymphoma MMLV insertion
region 1 (Bmi-1), stem cell factor 1 (SCF-1) and Notch1,
in line with the accepted stem-cell phenotype [7,8].
The first report on the identification of stem cells in ovar-
ian cancer came from our lab. Briefly, we had earlier iso-
lated nineteen single cell clones from the ascites of a
patient with advanced serous ovarian carcinoma [7].
While all clones possess stem cell-like characteristics, two
of them were found to be tumorigenic and could also
grow in an anchorage-independent manner in vitro as
spheroids. Tumors established from these clones in ani-
mal models were similar to those in the human disease in
their histopathology and cell architecture. Further, even
on serial transplantation, cells of both clones continued
to establish tumors. Taken together, the functionality of
these clones suggested their identity to be that of cancer
stem cells.
Generation of CSC from transformed stem cells 
vs. tumor cell dedifferentiation
Although CSCs are being increasingly reported, the exact
origin of these cells is still debated. Do CSCs directly orig-
inate from normal stem cells, or are they the outcome of
ovarian cancer cells that have gained stem cell properties?
The former school of thought surmises that normal tissue
stem cells give rise to CSCs is supported by the striking
degree of similarity between somatic stem cells and cancer
cells. As described earlier, this includes the sharing of phe-
notypic markers as well as the fundamental abilities to
self-renew and produce hierarchies of cells at varying lev-
els of differentiation [76-81]. Given these common
attributes, it has been proposed that cancers are caused by
transforming mutations that occurred in tissue-specific
stem cells. This hypothesis is further supported by the fact
that among all the cells within a particular tumor, only a
small fraction of CSCs are able to regenerate the entire
tumor; serial transplantation studies using CSCs and
OCIC are able to continue establishing tumors [7,8]. Fur-
ther studies should provide important insights into the
dynamic relationship between developmental plasticity,
environmental context and neoplastic transformation
[82].
The second school of thought generates the ongoing
debate whether tumor growth needs to be driven by CSCs
at all [83]. Thus, the alternative hypothesis suggests that
reprogramming of cancer cells by dedifferentiation will
confer stem-like functions (reviewed in [84]. Tumor cells
may also progressively acquire stem cell properties as a
consequence of oncogene-induced plasticity [84]. An
example in point is that committed myeloid progenitor
cells have been shown to acquire leukemia stem cells
properties without changing their overall identity, and
behave like stem cells through re-activation of genes nor-
mally expressed in normal primitive hematopoietic stem
cells [85]. It is difficult to attribute the appearance of stem
cells in EOC to specifically transformation of normal OSE
or to dedifferentiation, but it is considered to reflect
anomalous organogenesis and developmental patterning
within the transformed tissue [32]. The current definition
of a CSC thus, emphasizes its stem cell-like properties,
and implies its origin from stem, progenitor or differenti-
ated cells.Page 4 of 11
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profiling the comprehensive model of single cell clones
described above as well as several primary tumor samples
for mitochondrial (mtDNA) mutations [86]. Divergence
of the two cancer stem cell clones expressing a highly
mutant mtDNA profile, from normal stem cell clones that
express the germline profile, was very distinct. In addition
to the two cancer stem cell clones, the mutant group also
included 3 non-tumorigenic clones. The latter clones later
showed a propensity to undergo transformations. Our
findings suggest that stem cell transformation could be
the underlying cause of ovarian cancer and that continu-
ing stochastic events of stem and progenitor cell transfor-
mation define the increasing aggression that is
characteristically associated with the disease.
EMT and cancer stem cells
Recently, the induction of EMT in immortalized human
mammary epithelial cells (HMLEs) were reported to result
in the acquisition of not only mesenchymal traits, but also
expression of stem-cell markers and formation of mam-
mospheres, a property associated with mammary epithe-
lial stem cells [6]. Furthermore, stem -like cells isolated
from HMLE cultures form mammospheres express mark-
ers similar to those of HMLEs that have undergone EMT
[6]. The intrinsic property of OSE to undergo EMT, gain
mesenchymal and stem-cell markers [5] suggests that
these cells may have a propensity to re-acquire a stem cell-
like phenotype. Further, OCIC, as in the mammospheres,
also exhibit classical stem-cell properties [8], suggesting
that a similar situation is likely to occur in the context of
ovarian cancer.
Epigenetics of cancer stem cells
Promotion and expansion of stem/progenitor cells predis-
poses cancer development by expanding a pluripotent
population of cells that would otherwise be quiescent or
undergo appropriate differentiation [82]. While genetic
contributions have been well documented in carcinogen-
esis, they do not solely explain the origin of most tumors
[87]. CSCs harboring similar genetic abnormalities as the
parental tumors, are still distinctly different, and may be
explained by epigenetic changes [88]. The involvement of
widespread epigenetic alterations is now known to occur
very early in carcinogenesis even prior to genetic muta-
tions, and suggests such mechanisms to mediate transfor-
mation [87]. Alterations include global DNA
hypomethylation with localized hypermethylation, and
aberrant patterns of histone modifications including atyp-
ical lysine acetylation and methylation [60], provide evi-
dence of "epigenetic progenitor model of human cancer"
theory [87]. Such early epigenetic events would further
evolve during expansion of a progenitor cell pool, fol-
lowed by hyperplasia and an initiating genetic or epige-
netic mutation. Continuing mutagenesis and alterations
in chromatin patterns and transient silencing of regula-
tory genes in stem cells possibly would further facilitate
aberrant cell functioning during tumor initiation and pro-
gression [89].
Epigenetic modulation of gene expression is also known
to be essential for normal function of stem cells. Both nor-
mal and malignant embryonic cells generally lack the
hypermethylation of DNA found in adult cancers. How-
ever, the pattern of epigenetic regulation is disrupted and
highly abnormal in cancers, often highlighted by aberrant
promoter CpG island hypermethylation and transcrip-
tional silencing of tumor suppressor genes and pro-differ-
entiation factors. Many of the aberrant chromatin
modifications are repressive, and act to silence tumor sup-
pressor genes [60] several genes of which normally con-
tribute to differentiation [90]. In normal stem cells, a large
majority of such genes are identified in association with a
bivalent histone mark in their promoter regions, consist-
ing of a co-occupancy of an activating H3K4me2 mark
with a repressive H3K27me3 modification [91,92]. Such a
co-existence of activating and repressive marks, in differ-
entiation-control genes, has been suggested to maintain
these genes poised in a 'transcription-ready' state, poised
for up- or down- regulation [93,94]. The bivalent state of
H3K4me2 – H3K27me3 exists in immature stem and pro-
genitor cells as a mechanism of gene regulation, and is
more recently identified in adult tumors at a large percent-
age of genes, revealing a novel chromatin-based mecha-
nism for maintaining pluripotency [92]. The
identification of such features in pluripotent embryonal
carcinoma cells has led to the realization that bivalent epi-
genetic marks H3K4me2/H3K9me2 and H3K4me2/
H3K9me3 are also additionally associated with CSCs
[89].
Ezh2, a polycomb repressive complex (PRC)-dependent
histone-lysine methyltransferase is increasingly elevated
during prostate cancer progression [95]. During EOC dis-
ease progression, DNMT1 expression is elevated [39], is
correlated with increased DNA and histone methylation
with advanced, chemoresistant ovarian cancer [65,96,97].
Epigenetic regulation of CSCs is thus, a rapidly emerging
area wherein relatively knowledge exists at present, but
continuing understanding of the normal mechanisms
could reveal the aberrant features that mediate and main-
tain the transformed state, especially in solid malignan-
cies [87,89,98].
miRNA as targets and/or mediators of 
epigenetic signaling
MicroRNAs (miRNAs, or miRs) are an abundant class of
small noncoding RNAs that function as negative gene reg-
ulators. These small, evolutionarily conserved, noncoding
RNAs (approximately 20–22 nucleotides) are the result ofPage 5 of 11
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ical functions in cell proliferation, apoptosis, and differ-
entiation through regulation of the expression of several
critical genes in development and organogenesis
(reviewed in [99]. Although a relatively new field, there is
already a clear and definitive role for miRNA that function
as tumor suppressors were found to be markedly down-
regulated in malignant transformation and tumor pro-
gression [63]. miRNA has also been shown to directly reg-
ulate tumor suppressors and oncogenes in ovarian cancer
[62,99-105].
As is well understood, promoter hypermethylation may
induce gene silencing. Recently, epigenetics has also been
shown to directly impact miRNA expression [106,107].
Furthermore, it is now appreciated that many miRNAs are
located within introns of genes, and may be subjected to
epigenetic silencing along with the preceding gene [108].
What was once seen as epigenetic downregulation of a sin-
gle gene has now expanded to include miRNA and the
numerous potential downstream pathways of the miRNA
targets; for example, the hypermethylation and subse-
quent repression of let7a-3 in ovarian cancer [109].
DNMTi therapy has been shown to reverse hypermethyla-
tion and increase miRNA expression [103], further pro-
viding evidence that epigenetics can directly silence
miRNA. miRNA gene silencing in stem cells has been
shown to be mediated by Polycomb group proteins,
resulting in tissue-specific expression in differentiated
cells [110], revealing an epigenetic-mediated regulation of
miRNA as yet another regulatory mechanism that influ-
ences stemness and cell differentiation. However, the reg-
ulation of miRNAs at the transcriptional level remains
relatively unexplored.
The use of miRNA microarrays are proving useful in delin-
eating the complex miRNA regulatory networks. In com-
bination with gene expression and ChIP arrays, such
miRNA analyses will allow correlations to be made
between epigenetic marks and subsequent changes in
gene expression, miRNA expression, and impact on
downstream signaling pathways [56,62,63,111-113]. Fur-
thermore, miRNA may join the ranks of biomarkers;
expression of the miRNA-200 family has been shown to
define the epithelial ovarian cancer phenotype [114,115].
Therefore, transcriptional, epigenetic and now miRNA-
mediated regulatory mechanisms all appear to coordinate
the molecular mechanisms driving pluripotency and self-
renewal in ovarian cancer [116].
Targeted therapy to advanced disease and 
cancer stem cells
The rate of mortality in ovarian cancer has changed little
in the past three decades [1,2]; drug resistance remains the
major therapeutic barrier [3]. Early detection is critical
[117], and many genes that are specifically overexpressed
in the context of ovarian cancer provide potential biomar-
kers for ovarian cancer detection [33-37,118]. Changes in
gene expression of these biomarkers may also be used as
surrogate tests for chemotherapy response, such as
CA125, osteopontin, MUC1, and HE4 [40,51]. Although
chemotherapeutics target rapidly proliferating tumor cells
and provide temporary remission, only the bulk of tumor
cells is destroyed, and drug-resistant stem cells remain. In
line with clinical observations, it is currently believed that
recurrent disease is repopulated by these chemoresistant
CSCs [119] that retain their drug-resistant phenotype,
proliferate, pass along drug resistance to their progeny
and thus repopulate a tumor that is fully refractory to fur-
ther treatment [1,3]. Indeed, such cells from solid tumors
have been directly demonstrated as being chemo- and
radioresistant, with a potential role in disease recurrence
[120-122]. CSCs and their relevance for tumor progres-
sion and tumor therapy have been extensively reviewed
[123].
Epigenetics-based gene therapy
One therapeutic approach for targeting chemoresistance
may be to reverse the epigenetic marks in chemoresistant
cells. Small interfering RNA (siRNA) raised against
DNMT1 has been shown to restore estrogen receptor-
alpha (ERα) signaling in ERα-negative human breast can-
cer cell lines, thus enabling the use of antiestrogens as
therapy [124] while overexpression of a dominant-nega-
tive histone H3 lysine 27 mutant (H3K27R) de-repressed
epigenetically silenced tumor suppressor genes and
reversed drug-resistance in ovarian cancer cells [65]. Such
studies provide a proof-of-concept that epigenetic altera-
tion can directly impact ovarian cancer chemosensitivity.
Several chemical inhibitors of epigenetic enzymes, target-
ing DNMT and histone deacetylases (HDAC), have shown
promising anti-tumorigenic effects for some malignancies
(reviewed in [125,126]. Treatment of cancer cells with the
DNMT inhibitors 5-aza-dC, decitabine and zebularine
show promise in reversal of repressive histone mark pat-
terns and resensitization of ovarian cancer cells to chemo-
therapy [127,128], and several are currently in clinical
trials [125,126].
Inhibitors of class I histone deacetylases (HDACi) have
been shown to suppress ovarian cancer cell growth and
provide an option for clinical use [129]. HDACi are
divided into four groups: short-chain fatty acids,
hydroxamic acids, cyclic tetrapeptides, and benzamides.
The small-chain fatty acids butyrate, and valproic acid
(VPA) (originally regarded as anti-epileptic drug), were
the first known HDAC inhibitors [130,131]. Although not
exceedingly specific, these compounds laid the founda-
tion of HDACi and are tools for studying the structure and
mechanism of HDACi. Newer HDACi, like suberoylani-Page 6 of 11
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designed with high affinity for the zinc ion within the
HDAC catalytic domain [132]. The HDACi depsipeptide
has the capability to activate silenced genes by decreasing
both CpG and H3K9 methylation at gene promoters, sug-
gesting HDAC inhibition induces additional chromatin
regulation aside from histone acetylation [133]. Indeed, it
has been established that combinations of DNA methyla-
tion and HDACi are more potent for gene re-expression
than either alone [97,134]. VPA, SAHA, depsipeptide, and
other HDACi are currently in clinical trials, alone and in
combinations with DNMTi (reviewed in [125,126]).
Combinatorial epigenetic therapy may also be useful in
targeting stem cells; DNMT1 gene knockout combined
with HDACi has been shown to be lethal to embryonic
stem cells [135]. Such therapy may therefore extended to
targeting against cancer stem cells. One potential draw-
back of epigenetic therapy is the possibility that these
agents can inhibit or reverse normal developmental proc-
esses or accelerate cellular differentiation and tissue age-
ing [136-138]. This may not be surprising since most
HDACi and DNMTi compounds were originally discov-
ered as differentiating agents [126,139-141], and must be
considered alongside efficacy.
miRNA and siRNA therapy
siRNA have been employed as transcriptional inhibitors
of oncogene and growth factor signaling. Oct4 plays a key
role in the maintenance of pluripotency and proliferation
potential of stem cells, and siRNA directed against OCT4
induces cell apoptosis in stem cells [142]. Synthetic
miRNA have been utilized to target glioma-associated
antigen 1 transcription factor, and induce apoptosis in
pancreatic tumor cells, providing an alternative to siRNA-
mediated gene silencing [143]. The concept of siRNA and
miRNA-mediated gene silencing is solid, but is limited
clinically by methods of delivery [144].
miRNA expression is correlated with various human can-
cers and indicates that deregulated miRNAs can function
as classical tumor suppressors and oncogenes [145,146].
miRNAs have been shown to repress the expression of
important cancer-related genes and might prove useful in
cancer diagnosis and therapy. For example, let-7 miRNAs
has been found to be downregulated in different types of
cancer, suggesting that it acts as a tumor suppressor genes
[146]. The oncogene RAS is one mRNA transcript targeted
by miRNA let-7, revealing a possible mechanism for let-7-
mediated tumor suppression [147]. Several groups have
also described the deregulated expression of miRNAs in
cancer by microarray analysis. miRNAs expression profil-
ing can distinguish between different types of cancers and
even between different subtypes of tumors from the same
cancer type [148-150].
An individual miRNA may have dozens or even hundreds
or transcriptional targets [99]. Based on this premise,
miRNA-targeted therapies have introduced the revolu-
tionary therapeutic concept of 'one hit, multiple targets'
[151]. Therapeutic interventions for miRNAs could be
used to 'correct' the miRNA expression levels and, conse-
quently, 'normalize' the expression of their numerous
mRNA targets in cells, some of which may be encoded by
oncogenes and tumor suppressor genes [151]. An impor-
tant chicken-or-egg question remains: Are miRNAs differ-
entially expressed as a consequence of the cancer state, or
does cancer cause the deregulated expression of miRNAs?
Both scenarios are likely true; miRNA have been shown to
be epigenetically silenced [106-108], and miRNA have
been shown to modulate expression of epigenetic
machinery in human cancers [152,153].
Conclusion
The inadequacy of standard therapies is currently being
considered as a failure of existing chemotherapeutics to
target ovarian CSCs resulting in inevitable relapse
[119,154]. As CSCs are believed to be responsible for per-
petuating recurrent and chemorefractory disease[119], a
great need exists for therapies that target the small percent-
age of tumorigenic progenitors and may provide a much
needed breakthrough in treatment of advanced cancer
and chemoresistant disease [119]. Integrating genomic,
epigenomic, and miRNA microarray technologies have
begun to reveal a coordinated network of epigenetic-
mediated regulation of gene and miRNA expression
which promotes the stem cell phenotype [110]. We can
soon expect an explosion in the volume of epigenetic data
available as continued advances in array-based whole-
genome/epigenome analysis more clearly define the
genome and epigenome of cancer and CSCs. Cancer epi-
genetics research has led to the field of translational epige-
netics, a growing range of epigenetic inhibitors, and raised
intense interest in the development of additional epige-
netic drugs with greater specificity and efficacy in clinical
settings. Great potential lies in the development of novel
epigenetic-based therapies targeting DNA methyltrans-
ferases and histone deacetylases [155].
The development of novel therapeutics requires the con-
tinuing application of existing technologies in genomics,
proteomics and bioinformatics to resolve the complex
relationships involved. Continued investigation of genet-
ics, epigenetics, and the mechanisms responsible for the
initiation and progression of ovarian cancer will allow for
further understanding of the relationship between stem
cell-based tumorigenesis and epigenomic alterations. Fur-
ther characterization of tumorigenic cell populations will
identify molecules expressed in CSCs that could then
serve as targets. With the identification of definitive tar-
gets, this fraction of cancer cells that can rapidly developPage 7 of 11
(page number not for citation purposes)
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quently, defining the unique properties of ovarian CSCs
remains a high priority for developing early diagnostic
and effective therapeutic strategies against ovarian cancer.
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